Status:
COMPLETED
A Study of Chinese Adults With Lymphoma
Lead Sponsor:
Takeda
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The main aim of this study is to improve methods of clinical testing and therapy for lymphoma participants. This study will involve collecting information about participants from past medical records...
Detailed Description
This is an observational, non-interventional, retrospective study to evaluate staining and interpretation concordance of CD30 expression detected by 9 immunohistochemistry (IHC) assays and VENTANA CD3...
Eligibility Criteria
Inclusion
- Participants with diagnosis of cHL, ALCL, MF-LCT, DLBCL, PMBL, ENKTCL, PTCL-NOS, AITL and PCCD30+TCLPD.
- Participants with available FFPE samples archived within 3 years.
- Whose tissue slides of FFPE samples were previously IHC stained, their CD30 expression showed as well-localized positive stain and investigator deemed appropriate for evaluation.
Exclusion
- Sample is not sufficient for CD30 testing.
- Incomplete sample information including key demographic characteristic, clinicopathological parameters and previous CD30 testing results.
Key Trial Info
Start Date :
October 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2024
Estimated Enrollment :
934 Patients enrolled
Trial Details
Trial ID
NCT05288491
Start Date
October 31 2022
End Date
June 20 2024
Last Update
August 12 2024
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100000
2
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100000
3
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100000
4
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350000